Risk factors for humoral myocardial rejection during the first year after heart transplantation
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Objective: to identify risk factors for antibody-mediated myocardial rejection (AMR) during the first year following heart transplantation (HT). Materials and methods. This retrospective study included 162 patients who underwent HT at Almazov National Medical Research Centre between 2010 and 2024. Clinical, laboratory, immunological, and morphological data were analyzed. Sensitization was assessed using Luminex multiplex assays and solid-phase ELISA. AMR was diagnosed based on endomyocardial biopsy with morphological and immunohistochemical evaluation in accordance with the 2013 ISHLT classification. Hemodynamically significant rejection was defined as AMR II–III in combination with graft dysfunction and/or the presence of donorspecific antibodies (DSA). Patients were stratified into three groups: (1) no sign of AMR (control); (2) isolated morphological signs of AMR (AMR II); and (3) hemodynamically significant AMR (AMR III, or AMR II with DSA and/or echocardiographic evidence of graft dysfunction). Discriminant analysis was used to evaluate the factors associated with the development of AMR. Results. Morphological signs of AMR were identified in 36.2% of patients, including 9.9% with hemodynamically significant rejection requiring specific therapy. Patients with AMR before HT showed significantly higher sensitization to HLA class I and II antigens (MFI >5000; p < 0.05), and following HT, a statistically significant excess of de novo antibodies persisted for 6–12 months compared with the control group (p < 0.05). In addition, AMR was associated with lower tacrolimus levels during the first two weeks after HT (p = 0.002) and reduced antimetabolite doses in the first month post-transplant (p < 0.001). Discriminant analysis of 15 variables yielded a model incorporating 9 significant predictors, enabling statistically reliable differentiation of patients with hemodynamically significant rejection from other groups (F(18,222) = 12.463; p < 0.00001). Conclusion. High levels of HLA sensitization before transplantation, suboptimal immunosuppression in the early postoperative period, and predictors identified in the discriminant analysis model are associated with an increased risk of developing hemodynamically significant AMR. The proposed model may be used for risk stratification and to individualize post-transplant follow-up.
Fields of Study & Subjects
Transplantation: Methods and Outcomes
Renal Transplantation Outcomes and Treatments
Organ and Tissue Transplantation Research
Publication details
- Journal / source
- Russian Journal of Transplantology and Artificial Organs
- Volume
- 28
- Issue
- 1
- Pages
- 128–137
- Publication date
- 31 March 2026
- Language
- EN